As a globally leading pharmaceutical and medical device company, Johnson & Johnson (JNJ) stands out as an important choice for retirement investors seeking stable income, thanks to its exceptional record of dividend growth. As of April 6, the company’s market capitalization reached $580.37 billion, with trailing twelve-month revenue of $94.2 billion, gross profit of $63.9 billion, and a five-year annualized return of 8.34%. The company was founded in 1886.
Johnson & Johnson’s two core business segments are Innovative Medicine and MedTech. The Innovative Medicine division focuses on the research, development, and sale of prescription drugs, while the MedTech segment manufactures medical devices, including Acuvue contact lenses. Prior to 2023, Johnson & Johnson also had a robust Consumer Health division, whose products included well-known household brands such as Tylenol and Band-Aid. This division was later spun off as an independent company, Kenvue (KVUE), and at the end of 2025, an agreement was reached for consumer goods giant Kimberly-Clark (KMB) to acquire it for $48.7 billion.
Johnson & Johnson is a member of the “Dividend Kings” — an elite group of companies that have raised their dividends annually for at least 50 consecutive years. In the healthcare sector, only four companies have achieved this distinction, including AbbVie (ABBV). Johnson & Johnson leads the group with a record of 63 consecutive years of dividend increases, nine years longer than the next longest record among the other three healthcare Dividend Kings (54 years).
This achievement is no accident. Johnson & Johnson has a robust business strategy that it executes effectively in both good and bad markets. Following the spinoff and subsequent acquisition of its consumer health business, Johnson & Johnson has now transformed into a pure-play healthcare company.
Although focused on the healthcare sector, Johnson & Johnson maintains a diversified advantage. It is not only one of the largest pharmaceutical companies in the world but also a leading medical device manufacturer. The medical device business generates more stable cash flows, which helps balance the inherent patent expiration risks of the pharmaceutical industry — a major advantage for long-term investors.
Notably, the company continues to optimize its operations and plans to spin off its orthopedics business in 2027. After the spinoff, Johnson & Johnson’s MedTech business will focus on cardiovascular, surgical, and vision care. However, its pharmaceutical business (which accounts for nearly two-thirds of revenue) will remain the primary driver. Additionally, Johnson & Johnson holds an AAA credit rating, the highest possible, indicating a very solid financial foundation for its dividends.
Johnson & Johnson’s dividend yield is approximately 2.2%. While this is double the 1.1% yield of the S&P 500 index, it remains below the 4% target that many dividend investors seek. Nevertheless, for investors seeking stable dividends from a pharmaceutical company, this diversified healthcare giant surpasses all other options in key aspects.
Summary: With its 63-year record of consecutive dividend increases, Johnson & Johnson stands as one of the most reliable companies in the healthcare sector for dividend stability. Its AAA credit rating and dual-engine business structure of pharmaceuticals and medical devices provide a solid foundation for long-term dividend payments. Although its current 2.2% dividend yield is not the highest in the market, Johnson & Johnson remains a highly attractive choice for investors who prioritize reliability and sustainability of growth.
